The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Controlled Trial of Nebulized Gentamicin in Non–Cystic Fibrosis Bronchiectasis
Abstract
RATIONALE: Bronchiectasis is a chronic debilitating disease with few evidence-based long-term treatments. OBJECTIVES: A randomized controlled trial assessing the efficacy of nebulized gentamicin therapy over 1 year in patients with non-cystic fibrosis bronchiectasis. METHODS: Sixty-five patients were randomized to either twice-daily nebulized gentamicin, 80 mg, or nebulized 0.9% saline, for 12 months. All were reviewed at three-monthly intervals during treatment and at 3 months' follow-up. MEASUREMENTS AND MAIN RESULTS: At each review the following were assessed: quantitative and qualitative sputum bacteriology; sputum purulence and 24-hour volume; FEV(1), FVC, and forced expiratory flow, midexpiratory phase; exercise capacity; Leicester Cough Questionnaire and St. George's Respiratory Questionnaire; and exacerbation frequency. Fifty-seven patients completed the study. At the end of 12 months' treatment, compared with the saline group, in the gentamicin group there was reduced sputum bacterial density with 30.8% eradication in those infected with Pseudomonas aeruginosa and 92.8% eradication in those infected with other pathogens; less sputum purulence (8.7% vs. 38.5%; P < 0.0001); greater exercise capacity (510 [350-690] m vs. 415 [267.5-530] m; P = 0.03); and fewer exacerbations (0 [0-1] vs. 1.5 [1-2]; P < 0.0001) with increased time to first exacerbation (120 [87-161.5] d vs. 61.5 [20.7-122.7] d; P = 0.02). The gentamicin group had greater improvements in Leicester Cough Questionnaire (81.4% vs. 20%; P < 0.01) and St. George's Respiratory Questionnaire (87.5% vs. 19.2%; P < 0.004) score. No differences were seen in 24-hour sputum volume, FEV(1), FVC, or forced expiratory flow, midexpiratory phase. No P. aeruginosa isolates developed resistance to gentamicin. At follow-up, all outcome measures were similar to baseline. CONCLUSIONS: Regular, long-term nebulized gentamicin is of significant benefit in non-cystic fibrosis bronchiectasis but treatment needs to be continuous for its ongoing efficacy. Clinical trial registered with www.clinicaltrials.gov (NCT 00749866).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Celli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., Buist, A. S., Calverley, P. M. A., Chavannes, N., Dillard, T., Fahy, B., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,421
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035 · cited 7×
“The LCQ and the SGRQ were completed.”
BackgroundInfluentialThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Antibiotic Therapy in Exacerbations of Chronic Obstructive Pulmonary Disease
ANTHONISEN, N. R., MANFREDA, J., WARREN, C. P. W., HERSHFIELD, E. S., HARDING, G. K. M., & NELSON, N. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-2-196 · Cited by 2,492
Birring, S. S. (2003) · Thorax · doi:10.1136/thorax.58.4.339 · Cited by 1,062
Inflammation: a two-edged sword--the model of bronchiectasis.
Pj, C. (1986) · PubMed · Cited by 571
Barker, A. F. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012519 · Cited by 551
Revill, S. M., Morgan, M. D. L., Singh, S. J., Williams, J., & Hardman, A. E. (1999) · Thorax · doi:10.1136/thx.54.3.213 · Cited by 462
Computed Tomography of Bronchiectasis
Naidich, D. P., McCauley, D. I., Khouri, N. F., Stitik, F. P., & Siegelman, S. S. (1982) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198206000-00001 · Cited by 450
Cited by
European Respiratory Society guidelines for the management of adult bronchiectasis
Polverino, E., Goeminne, P. C., McDonnell, M. J., Aliberti, S., Marshall, S. E., Loebinger, M. R., Murris, M., Cantón, R., Torres, A., Dimakou, K., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00629-2017 · Cited by 1,333
Self-citationThe bronchiectasis severity index. An international derivation and validation study
Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1575oc · Cited by 1,093
Self-citationKnowles, M. R., Daniels, L. A., Davis, S. D., Zariwala, M. A., & Leigh, M. W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201301-0059ci · Cited by 517
Antibiotic treatment of biofilm infections
Ciofu, O., Rojo‐Molinero, E., Macià, M. D., & Oliver, A. (2017) · APMIS · doi:10.1111/apm.12673 · Cited by 422
Chalmers, J. D., Moffitt, K. L., Suarez-Cuartin, G., Sibila, O., Finch, S., Furrie, E., Dicker, A., Wrobel, K., Elborn, J. S., Walker, B., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201605-1027oc · Cited by 416
Self-citation
Metadata
- Authors
- Murray, M. P., Govan, J. R. W., Doherty, C. J., Simpson, A. J., Wilkinson, T. S., Chalmers, J. D., Greening, A. P., Haslett, C., & Hill, A. T.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-15
- Volume
- 183
- Issue
- 4
- Pages
- 491-499
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2073471936
- Cited by
- 297
- References
- 30
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Controlled Trial of Nebulized Gentamicin in Non–Cystic Fibrosis Bronchiectasis. https://app.cochat.ai/papers/10.1164/rccm.201005-0756oc
- The paper
- Murray, M. P., Govan, J. R. W., Doherty, C. J., Simpson, A. J., Wilkinson, T. S., Chalmers, J. D., Greening, A. P., Haslett, C., & Hill, A. T. (2011). A Randomized Controlled Trial of Nebulized Gentamicin in Non–Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201005-0756oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.